Consistent with this notion, a recent publication revealed that triple combination treatments of statins and antibodies targeting PCSK9 and ANGPTL3 yielded additive effects on cholesterol and atherosclerosis reductions in mice (59). Here, PCSK9 is linked to atherosclerosis.